
Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – HC Wainwright issued their Q4 2027 earnings estimates for shares of Candel Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the company will earn ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.29) per share.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06.
Read Our Latest Stock Report on CADL
Candel Therapeutics Price Performance
Candel Therapeutics stock opened at $5.81 on Monday. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $14.00. The firm has a 50 day moving average price of $9.61 and a 200 day moving average price of $8.39. The company has a market cap of $444.58 million, a price-to-earnings ratio of -3.93 and a beta of -0.27. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09.
Institutional Trading of Candel Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. AlphaCentric Advisors LLC lifted its position in Candel Therapeutics by 4.3% during the third quarter. AlphaCentric Advisors LLC now owns 38,259 shares of the company’s stock valued at $399,000 after buying an additional 1,576 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Candel Therapeutics by 19.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company’s stock worth $152,000 after acquiring an additional 2,301 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Candel Therapeutics by 12.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock valued at $149,000 after acquiring an additional 3,400 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at $41,000. Finally, Profund Advisors LLC lifted its holdings in shares of Candel Therapeutics by 16.1% during the 3rd quarter. Profund Advisors LLC now owns 33,301 shares of the company’s stock valued at $348,000 after acquiring an additional 4,624 shares in the last quarter. Institutional investors and hedge funds own 13.93% of the company’s stock.
Key Headlines Impacting Candel Therapeutics
These are some of the CADL headlines that stood out recently:
- Positive Sentiment: A Seeking Alpha contributor upgraded Candel despite the filing delay, indicating a more constructive view of the company’s prospects. Candel Therapeutics: Upgrade Despite The Recent Prostate Filing Delay
- Negative Sentiment: Two law firms announced investigations into whether Candel’s statements about the BLA timeline violated securities laws. These are allegations under investigation, not findings of wrongdoing, but add legal and reputational uncertainty for investors. Levi & Korsinsky investigation notice Hagens Berman investigation announcement
- Negative Sentiment: Canaccord Genuity and Stifel Nicolaus also reduced their price targets, adding to evidence that analysts are adjusting expectations following the filing delay. Canaccord price-target update Stifel price-target update
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories
- Five stocks we like better than Candel Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
